Core Viewpoint - The Hong Kong stock market welcomed three new listings on February 6, including Zhuozheng Medical, which experienced a significant price increase of over 34% at the time of reporting [2][3]. Group 1: Zhuozheng Medical's IPO Performance - Zhuozheng Medical's public offering was oversubscribed by 2730.73 times, with 475,000 shares allocated for public sale, representing approximately 10% of the total shares offered [3]. - The international placement for Zhuozheng Medical was oversubscribed by 5.79 times, with 4.275 million shares allocated, accounting for 90% of the total shares offered [5]. - The final offering price for Zhuozheng Medical was HKD 59.90 per share, raising a net amount of HKD 209 million, with a current share price of HKD 80.40, resulting in a profit of HKD 1,025 per lot [6]. Group 2: Company Overview and Market Position - Zhuozheng Medical is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market, targeting affluent consumers who prefer personalized care [6]. - The company operates 19 medical service institutions in major Chinese cities and has expanded internationally with operations in Singapore and Malaysia [6]. - According to a Frost & Sullivan report, Zhuozheng Medical is the third-largest private mid-to-high-end healthcare service provider in China, holding a market share of 2.0% as of 2024 [8]. Group 3: Financial Performance - Zhuozheng Medical's revenue has shown significant growth, increasing from RMB 473 million in 2022 to RMB 959 million in 2024, with revenue for the first eight months of 2025 reaching RMB 696 million, up from RMB 615 million in the same period of 2024 [8]. - The company achieved profitability in 2024, recording a profit of RMB 83.21 million in the first eight months of 2025 [8].

Investment Rating - The report suggests a cautious subscription for the company [1] Core Insights - The company is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market, targeting affluent individuals with a disposable income exceeding RMB 200,000 [2] - The private mid-to-high-end healthcare service market in China is expected to grow significantly, with total revenue projected to increase from RMB 193 billion in 2020 to RMB 426 billion by 2024, reflecting a compound annual growth rate (CAGR) of 21.9% [3] - The company operates 19 healthcare facilities across major Chinese cities, including 17 clinics and 2 hospitals, and holds a market share of 2.0% in the private mid-to-high-end healthcare service sector [3] Financial Performance - The company's revenue for 2023 and 2024 is projected to be RMB 690 million and RMB 959 million, respectively, with a net profit of RMB 802 million expected in 2024 [4] - For the first eight months of 2025, the company has already achieved a revenue of RMB 696 million, representing a year-on-year growth of 14.0% [4] - The estimated market capitalization post-IPO is between HKD 37.15 billion and HKD 42.88 billion, with a price-to-earnings (PE) ratio of 26-31 times, indicating a relatively high valuation [4]

Investment Rating - The report suggests a cautious subscription for the company [1][4]. Core Insights - The company is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market, targeting affluent individuals with a disposable income exceeding RMB 200,000 [2]. - The private mid-to-high-end healthcare service market in China is expected to grow significantly, with total revenue projected to increase from RMB 193 billion in 2020 to RMB 426 billion by 2024, representing a compound annual growth rate (CAGR) of 21.9% [3]. - The company operates 19 healthcare facilities across major Chinese cities, including 17 clinics and 2 hospitals, and is positioned as the third-largest private mid-to-high-end healthcare service provider in China with a market share of 2.0% [2][3]. Financial Performance - The company's revenue for 2023 and 2024 is projected to be RMB 690 million and RMB 959 million, respectively, with a net profit of RMB 80.2 million expected in 2024 [4]. - For the first eight months of 2025, the company has already achieved a revenue of RMB 696 million, reflecting a year-on-year growth of 14.0% [4]. - The estimated market capitalization post-IPO is between HKD 3.715 billion and HKD 4.288 billion, with a price-to-earnings (PE) ratio of 26-31 times, indicating a relatively high valuation considering the company's growth potential [4].

Core Viewpoint - The company,卓正医疗, is launching a global offering of 4.75 million new shares on the Hong Kong Stock Exchange, aiming to raise approximately HKD 219 million for various strategic initiatives [2][5]. Group 1: Offering Details - The global offering consists of 4.75 million shares, with 4.275 million shares allocated for international offering and 475,000 shares for public offering in Hong Kong [2]. - The price range for the shares is set between HKD 57.70 and HKD 66.60, with a midpoint of HKD 62.15 expected to yield a net fundraising of approximately HKD 219 million after expenses [2]. - The public offering period is from January 29 to February 3, with the final price and allocation results to be announced on February 5, and trading to commence on February 6 [2]. Group 2: Use of Proceeds - The funds raised will be allocated as follows: 35% for building a talent pool and strategic partnerships, 30% for upgrading existing facilities and opening new ones, 25% for acquiring well-performing medical institutions in first and new first-tier cities, and the remaining for working capital [2]. Group 3: Investor Support - The offering has secured support from four cornerstone investors, including Health Vision,金域医学, 明略科技, and Galaxy Dynasty, committing to subscribe for shares totaling approximately USD 1.164 million (around HKD 90.79 million) [3]. - The cornerstone investors' commitments represent about 30.44% of the total offering shares, which could increase to 32.22% if the over-allotment option is fully exercised [4]. Group 4: Company Overview - 卓正医疗 focuses on providing private medical services to affluent individuals, operating 19 medical facilities in major Chinese cities and additional clinics in Singapore and Malaysia [5]. - The company is the third-largest private high-end medical service provider in China, with a market share of 2.0% based on projected 2024 revenue [5]. - Revenue has shown significant growth, increasing from RMB 473 million in 2022 to RMB 959 million in 2024, with a compound annual growth rate of 42.3% [5].

Core Viewpoint - 卓正医疗 is planning a global offering of 4.75 million shares, targeting the high-end medical service market in China, with a focus on affluent consumers seeking personalized care [1][2]. Company Overview - 卓正医疗 is a private medical service provider in China, emphasizing high-end medical services for affluent individuals with a disposable income exceeding RMB 200,000 [1]. - The company is the third-largest private high-end medical service provider in China, holding a market share of 2.0% in the private high-end medical service sector [2]. Market Insights - The total revenue of China's private high-end medical service market is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion by 2024, with a compound annual growth rate (CAGR) of 21.9% [2]. - By 2029, the market is expected to reach RMB 831.4 billion, continuing to grow at a CAGR of 14.3% from 2024 to 2029 [2]. Fundraising and Use of Proceeds - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares totaling approximately HKD 90.79 million [3]. - Assuming a mid-range offer price of HKD 62.15 per share, the company estimates net proceeds of approximately HKD 219.1 million from the global offering [4]. - The intended use of proceeds includes 35% for developing a talent pool for medical AI applications, 30% for upgrading existing facilities and establishing new ones, 25% for acquiring well-performing medical institutions, and 10% for working capital [4].

Group 1: Company Overview - The company, 卓正医疗, is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market targeting affluent individuals with a disposable income exceeding RMB 200,000 per year [2] - Established in 2012, the company operates 19 medical service institutions across major Chinese cities and has additional clinics in Singapore and Malaysia [3] - The company aims to expand its network through organic growth and strategic acquisitions, particularly in new first-tier cities [3] Group 2: Market Position and Growth - In 2024, private mid-to-high-end medical service institutions are expected to account for approximately 66.5% of the total revenue in China's mid-to-high-end medical service market, representing about 5.6% of the overall healthcare market [2] - The total revenue of China's private mid-to-high-end medical service market is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion in 2024, with a compound annual growth rate (CAGR) of 21.9% [2] - By 2029, the market is expected to reach RMB 831.4 billion, continuing to grow at a CAGR of 14.3% from 2024 to 2029 [2] Group 3: IPO Details - The company plans to offer 4.75 million shares globally, with 10% allocated for Hong Kong and 90% for international sales, and an additional 15% over-allotment option [1] - The expected price range for the shares is HKD 57.7 to 66.6, with trading anticipated to commence on February 6, 2026 [1] - The estimated net proceeds from the global offering are approximately HKD 219 million, which will be allocated for various strategic initiatives, including AI application development and upgrading existing medical facilities [4]

Group 1 - The company,卓正医疗, plans to conduct an initial public offering (IPO) from January 29 to February 3, 2026, offering 4.75 million shares at a price range of HKD 57.7 to 66.6 per share, with 10% allocated for Hong Kong and 90% for international sales [1] - The company targets the high-end medical service market in China, focusing on affluent individuals with a disposable income exceeding RMB 200,000, and aims to provide personalized care [2] - The private high-end medical service market in China is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion by 2024, with a compound annual growth rate (CAGR) of 21.9%, and is expected to reach RMB 831.4 billion by 2029, growing at a CAGR of 14.3% [2] Group 2 - The company operates 19 medical service institutions in China, including 17 clinics and 2 hospitals, and has plans for further expansion through organic growth and strategic acquisitions [3] - The company has secured cornerstone investment agreements totaling USD 11.64 million from several investors, which will be used to purchase shares at the IPO price [3] - The estimated net proceeds from the IPO, assuming a median price of HKD 62.15 per share, will be approximately HKD 219 million, allocated for various purposes including AI application development, upgrading existing facilities, and potential acquisitions [4]